List of patents in the Oncolytic virus industry

Patents where

Current Assignee

Industry

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 7809601 Intelligent performance-based product recommendation system	Patent 7809601 was granted and assigned to Johnson & Johnson on October, 2010 by the United States Patent and Trademark Office.		Johnson & Johnson	United States Patent and Trademark Office	7809601	October 5, 2010
‌ US Patent 10072082 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10072082 was granted and assigned to Bristol-Myers Squibb on September, 2018 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10072082	September 11, 2018
‌ US Patent 7582631 Substituted heterocyclic compounds and methods of use	Patent 7582631 was granted and assigned to Amgen on September, 2009 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7582631	September 1, 2009
‌ US Patent 6946079 Centrifugal filtration method for separating fibrin monomer from blood	Patent 6946079 was granted and assigned to Bristol-Myers Squibb on September, 2005 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	6946079	September 20, 2005
‌ US Patent 7332303 Product quality enhancement in mammalian cell culture processes for protein production	Patent 7332303 was granted and assigned to Bristol-Myers Squibb on February, 2008 by the United States Patent and Trademark Office.		Bristol-Myers Squibb	United States Patent and Trademark Office	7332303	February 19, 2008
‌ US Patent 9517264 Human FGF receptor and β-Klotho binding proteins	Patent 9517264 was granted and assigned to Amgen on December, 2016 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	9517264	December 13, 2016
‌ US Patent 11607451 Self-buffering antibody formulations	Patent 11607451 was granted and assigned to Amgen on March, 2023 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	11607451	March 21, 2023
‌ US Patent 7833979 Toxin peptide therapeutic agents	Patent 7833979 was granted and assigned to Amgen on November, 2010 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	7833979	November 16, 2010
‌ US Patent 10569014 Device and method for making aseptic connections	Patent 10569014 was granted and assigned to Amgen on February, 2020 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	10569014	February 25, 2020
‌ US Patent 11773106 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof	Patent 11773106 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11773106	October 3, 2023
‌ US Patent 11780848 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof	Patent 11780848 was granted and assigned to AbbVie Inc. on October, 2023 by the United States Patent and Trademark Office.	AbbVie Inc.	AbbVie Inc.	United States Patent and Trademark Office	11780848	October 10, 2023
‌ US Patent 10584170 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10584170 was granted and assigned to Bristol-Myers Squibb on March, 2020 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10584170	March 10, 2020
‌ US Patent 7763420 Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders	Patent 7763420 was granted and assigned to Genelux Corporation on July, 2010 by the United States Patent and Trademark Office.		Genelux Corporation	United States Patent and Trademark Office	7763420	July 27, 2010
‌ US Patent 10138299 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10138299 was granted and assigned to Bristol-Myers Squibb on November, 2018 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10138299	November 27, 2018
‌ US Patent 10266596 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266596 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266596	April 23, 2019
‌ US Patent 10266594 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266594 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266594	April 23, 2019
‌ US Patent 10266595 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10266595 was granted and assigned to Bristol-Myers Squibb on April, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10266595	April 23, 2019
‌ US Patent 10323093 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10323093 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10323093	June 18, 2019
‌ US Patent 10316091 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10316091 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10316091	June 11, 2019
‌ US Patent 10323092 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10323092 was granted and assigned to Bristol-Myers Squibb on June, 2019 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10323092	June 18, 2019
‌ US Patent 11345752 Optimization of antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof	Patent 11345752 was granted and assigned to Bristol-Myers Squibb on May, 2022 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	11345752	May 31, 2022
‌ US Patent 9061097 Drug delivery device	Patent 9061097 was granted and assigned to Amgen on June, 2015 by the United States Patent and Trademark Office.		Amgen	United States Patent and Trademark Office	9061097	June 23, 2015
‌ US Patent 10492990 Drug cassette, autoinjector, and autoinjector system	Patent 10492990 was granted and assigned to Amgen on December, 2019 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	10492990	December 3, 2019
‌ US Patent 10577423 Cancer immunotherapy by disrupting PD-1/PD-L1 signaling	Patent 10577423 was granted and assigned to Bristol-Myers Squibb on March, 2020 by the United States Patent and Trademark Office.	Bristol-Myers Squibb	Bristol-Myers Squibb	United States Patent and Trademark Office	10577423	March 3, 2020
‌ US Patent 11020537 Drug cassette, autoinjector, and autoinjector system	Patent 11020537 was granted and assigned to Amgen on June, 2021 by the United States Patent and Trademark Office.	Amgen	Amgen	United States Patent and Trademark Office	11020537	June 1, 2021

...

Results per page:

6,521 results

0 selected

6,521 results

0 selected